title: Transforming growth factor-beta 1 induces transforming growth factor-alpha promoter activity and transforming growth factor-alpha secretion in the human colon adenocarcinoma cell line FET.
abstract: FET cells are well differentiated human adenocarcinoma cells whose growth is partially inhibited (50-60%) by transforming growth factor-beta 1 (TGF-beta 1). In exponentially growing cultures, TGF-beta 1 induces the expression of transforming growth factor-alpha (TGF-alpha) by 3-fold. To determine whether this induction is the result of increased TGF-alpha promoter activity, FET cells were transiently transfected with a plasmid containing 2816 base pairs of the 5'-flanking region of the TGF-alpha gene linked to luciferase. Transfected FET cells treated with growth-inhibitory concentrations of TGF-beta 1 (10 ng/ml) showed up to a 10-fold increase in luciferase activity. The increase in luciferase activity was dose dependent through the normal physiological range of TGF-beta 1 (0.5-20 ng/ml), saturating at 10 ng/ml. This effect was also TGF-alpha promoter specific, inasmuch as the Rous sarcoma virus long terminal repeat used as a control remained relatively insensitive to the effects of TGF-beta 1. By using progressively smaller portions of the TGF-alpha promoter region, the TGF-beta 1-responsive element was mapped between base pairs -77 and -201 of the 5'-flanking region. TGF-beta 1 treatment also affected epidermal growth factor receptor levels. FET cells treated with TGF-beta 1 (10 ng/ml) for 48 h showed a 20% decrease in the number of epidermal growth factor receptors and a 2-fold increase in the number of high affinity epidermal growth factor receptors on their surface. These results indicate that TGF-beta 1 acts as a positive regulator of TGF-alpha transcription, and they suggest a possible mechanism by which these cells circumvent the growth-inhibitory effects of TGF-beta 1.
authors.affiliation: Bristol-Myers Squibb, Princeton, New Jersey 08540.
authors.forename: M J
authors.initials: MJ
authors.lastname: Lynch
authors.forename: L
authors.initials: L
authors.lastname: Pelosi
authors.forename: J M
authors.initials: JM
authors.lastname: Carboni
authors.forename: J
authors.initials: J
authors.lastname: Merwin
authors.forename: K
authors.initials: K
authors.lastname: Coleman
authors.forename: R C
authors.initials: RC
authors.lastname: Wang
authors.forename: P F
authors.initials: PF
authors.lastname: Lin
authors.forename: D L
authors.initials: DL
authors.lastname: Henry
authors.forename: M G
authors.initials: MG
authors.lastname: Brattain
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism*; D001483:Base Sequence; D003110:Colonic Neoplasms / Q000378:metabolism*; D016895:Culture Media, Serum-Free; D004790:Enzyme Induction; D006801:Humans; D008156:Luciferases / Q000096:biosynthesis / Q000235:genetics; D008969:Molecular Sequence Data; D011401:Promoter Regions, Genetic; D014162:Transfection; D016211:Transforming Growth Factor alpha / Q000096:biosynthesis* / Q000737:chemistry / Q000235:genetics; D016212:Transforming Growth Factor beta / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D016895:Culture Media, Serum-Free; D016211:Transforming Growth Factor alpha; D016212:Transforming Growth Factor beta; D008156:Luciferases